Master Alliance Provisions Guide (MAPGuide)

Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement

  • Protecting & sharing information | Confidentiality

<p><span style=”textdecoration: underline;”><strong>6. Manufacturing and Commercialization of Productstrong>span>p>
<p><strong>6.4 Marketing Materials.strong> Any marketing materials (including, but not limited to, advertisement and promotional materials) used by Licensee and its Third Party Resellers shall not contain any misstatements of fact, shall be fully compliant with the applicable laws, rules and regulations, and shall be distinct from, and not cause any confusion with, any marketing materials or Products used or sold by Gilead, or any marketing materials or products sold by Japan Tobacco. Any statements made in such marketing materials regarding Gilead, including without limitation statements made in reference to Licensees collaboration with Gilead, require Gileads prior written approval.p>
<p><span style=”textdecoration: underline;”><strong>11. Confidentiality and Publicationsstrong>span>p>
<p><strong>11.1strong> <strong>Confidential Information. strong>All technology and knowhow disclosed by one party (the “<em><strong>Disclosing Partystrong>em>”) to another party (the “<em><strong>Receiving Partystrong>em>”) hereunder (“<em><strong>Confidential Informationstrong>em>”) shall be used solely and exclusively by Receiving Party in a manner consistent with the licenses granted hereunder and the purposes of this Agreement as stated in the preamble and recitals hereto; maintained in confidence by the Receiving Party; and shall not be disclosed to any nonparty or used for any purpose except to exercise its rights and perform its obligations under this Agreement without the prior written consent of the Disclosing Party, except to the extent that the Receiving Party can demonstrate by competent written evidence that such information: (a) is known by the Receiving Party without obligations of confidentiality at the time of its receipt and, not through a prior disclosure by the Disclosing Party, as documented by the Receiving Partys business records; (b) is in the public domain other than as a result of any breach of this Agreement by the Receiving Party; (c) is subsequently disclosed to the Receiving Party on a nonconfidential basis by a third party who may lawfully do so; or (d) is independently discovered or developed by the Receiving Party without the use of Confidential Information provided by the Disclosing Party and, in the case of MPP as the Receiving Party, other than in connection with the MPP License Agreement, as documented by the Receiving Partys business records. Notwithstanding the foregoing, none of the technology and knowhow disclosed by Gilead through MPP under this Agreement shall be considered MPPs Confidential Information. Instead, all technology and knowhow disclosed by Gilead through MPP hereunder shall be deemed to be Gileads Confidential Information rather than MPPs Confidential Information. Where any technology and knowhow was originally disclosed by Licensee to MPP and, in turn, disclosed by MPP to Gilead, such technology and knowhow shall be deemed to be Licensees Confidential Information. Within thirty (30) days after any expiration or termination of this Agreement, Receiving Party shall destroy (and certify to the Disclosing Party such destruction) or return all Confidential Information provided by the Disclosing Party except as otherwise set forth in this Agreement. One (1) copy of the Confidential Information may be retained in the Receiving Partys files solely for archival purposes as a means of determining any continuing or surviving obligations under this Agreement. The confidentiality obligations under this Agreement shall survive this Agreement for a period of five (5) years. To the extent Gilead receives any Confidential Information from Licensee relating to EVG, EVG Product, EVG Combination Product or Quad, Gilead will have the right to disclose such Confidential Information to Japan Tobacco, provided such disclosure remains subject to the obligations of confidentiality and nondisclosure set forth in the Japan Tobacco Agreement.p>
<p><strong>11.2strong> <strong>Press Releasestrong>. Each party may disclose to third parties or make public statements, by press release or otherwise, regarding the existence of this Agreement, the identity of the parties, the terms, conditions and subject matter of this Agreement, or otherwise in reference to this Agreement, provided such disclosures or statements are accurate and complete with respect to the subject matter thereof and the information disclosed therein.p>
<p><strong>11.3strong> <strong>Use of Namestrong>. Except as provided for under Sections 6.5 and 11.2, no party shall use any other partys name, logo or trademarks for any purpose including without limitation publicity or advertising, except with the prior written consent of the other party. Licensee agrees not to use Japan Tobaccos name, logo or trademarks for any purpose except with the prior written consent of Japan Tobacco, except as provided for under Section 11.2.p>